The British Heart Foundation is pressing for a renewed focus on improving the diagnosis and management of familial hypercholesterolaemia, and adoption of a nationwide cascade screening programme for first-degree relatives. The article includes best practice tips for busy primary healthcare professionals.
Claire Bellone, clinical nurse specialist at the Chelsea & Westminster Hospital NHS Trust, gives her personal view on how primary healthcare professionals can work with women with menopausal symptoms and implement the recommendations of the NICE guideline on the diagnosis and management of menopause.
‘Issues & Answers in Cardiovascular Disease’ is the leading UK cardiovascular conferences for the whole primary care team. Expert presenters and a down-to-earth approach help health professionals translate the latest evidence into daily practice and optimise patient care. Participants also receive 6 hours CPD credits. Read the highlights from the 2016 conference and access presentation slides here.
The UK charity Heart Valve Voice has developed the first practical guidance in heart valve disease for primary care. The disease is under-diagnosed and yet is increasing in prevalence as the population ages, so there is a need for primary care to plan an appropriate response.
Sacubitril/valsartan (Entresto), the first angiotensin receptor-neprilysin inhibitor (ARNI), is a recently licensed medication that has been shown to improve outcomes for patients with symptomatic chronic HF with reduced ejection fraction (HF-REF) compared with current gold-standard treatment with an ACE inhibitor. This article describes the pharmacist’s role in supporting patients receiving sacubitril/valsartan.
Commissioning is not so different from seeing patients. As a GP you listen, examine, draw up a diagnosis and plan treatment. In commissioning, the community served by the clinical commissioning group (CCG) is the ‘patient’. When considering the introduction of a new treatment for heart failure (HF) such as sacubitril/valsartan (Entresto), we must consider not only its acquisition costs but also its potential benefits in improving patients' symptoms and reducing expensive hospital admissions.
Many patients with heart failure rely on practice nurses to monitor their care. A multidisciplinary team (MDT) integrated community approach has been endorsed by NICE guidelines when delivering HF care. This article provides practice nurses with the information they need to understand the condition, current treatment guidelines, and the new treatment – sacubitril/valsartan, the first-in-class angiotensin receptor-neprilysin inhibitor.
This article describes the use of sacubitril/valsartan – the first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) in primary care and how the new drug fits in the heart failure treatment pathway. Current guidelines and case studies are also explored to provide further understanding of this latest HF treatment to enter clinical use.